{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:41:02Z","timestamp":1771922462305,"version":"3.50.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aims to investigate the risk of drug-induced cataract and examine its epidemiological patterns using real-world data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from the FDA Adverse Event Reporting System (FAERS), spanning January 2004 to December 2024, were analyzed. A disproportionality analysis was conducted on the FAERS database using four quantitative measures\u2014reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS)\u2014to identify potential safety signals. The study categorized the identified cataract-induced drugs by risk level and quantitatively compared the time to onset across these categories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 671 drugs were reported to be associated with cataract in the FAERS database. Disproportionality analysis identified 64 drugs with a significant risk of cataract formation. The primary therapeutic classes included hormonal, oncological, and ophthalmic medications, along with drugs acting on the nervous system. The highest-risk drugs identified were omidenepag isopropyl, clobazam, and nitisinone, with BCPNN scores of 7.69, 7.36, and 6.02, respectively. Ophthalmic medications showed the shortest mean onset time for drug-induced cataract, averaging 120.29\u202fdays. The majority of affected individuals were female (67.59%) and elderly (mean age 63.85\u202f\u00b1\u202f14.54\u202fyears).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides real-world evidence regarding the risk of drug-induced cataract, offering empirical support for preventive strategies and informed clinical decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1758892","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T15:02:16Z","timestamp":1768575736000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug-induced cataract: a real-world study based on the food and drug administration adverse event reporting system database"],"prefix":"10.3389","volume":"13","author":[{"given":"Xianfen","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, The First People\u2019s Hospital of Chenzhou","place":["Chenzhou, Hunan, China"]},{"name":"Department of Ophthalmology, The First Affiliated Hospital of Jinan University","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First People\u2019s Hospital of Chenzhou","place":["Chenzhou, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinan","family":"Wu","sequence":"additional","affiliation":[{"name":"Eye Institute of Xiamen University, School of Medicine, Xiamen University","place":["Xiamen, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Jinan University","place":["Guangzhou, China"]},{"name":"Ophthalmic Center, The Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulun","family":"Ou","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First People\u2019s Hospital of Chenzhou","place":["Chenzhou, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Jinan University","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.ophtha.2025.02.010","article-title":"Cataract and risk of fracture: a systematic review, meta-analysis, and Bayesian network meta-analysis","volume":"132","author":"Gallo Afflitto","year":"2025","journal-title":"Ophthalmology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1001\/jama.2025.1597","article-title":"Cataracts: a review","volume":"333","author":"Chen","year":"2025","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1038\/s41433-024-02961-1","article-title":"Global estimates on the number of people blind or visually impaired by cataract: a meta-analysis from 2000 to 2020","volume":"38","year":"2024","journal-title":"Eye (Lond)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"10544","DOI":"10.3389\/ebm.2025.10544","article-title":"Dietary-related characteristics and cataract risk: evidence from a mendelian randomization study","volume":"250","author":"Li","year":"2025","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.18240\/ijo.2025.11.12","article-title":"Risk prediction model for cataract after vitrectomy surgery: a 2-year study on primary rhegmatogenous retinal detachment","volume":"18","author":"Gong","year":"2025","journal-title":"Int J Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1498191","DOI":"10.3389\/fphar.2025.1498191","article-title":"Real-world pharmacovigilance analysis of drug-related cataracts using the FDA adverse event reporting system database","volume":"16","author":"Li","year":"2025","journal-title":"Front Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"947659","DOI":"10.3389\/fmed.2022.947659","article-title":"Drugs associated with cataract formation represent an unmet need in cataract research","volume":"9","author":"Carlson","year":"2022","journal-title":"Front Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/cpt.3701","article-title":"FDA adverse event reporting system (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS","volume":"118","author":"Potter","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1177\/20420986251371983","article-title":"Real-world large sample evaluation of drug-related blepharoptosis: a pharmacovigilance analysis of the FDA adverse event reporting system database","volume":"16","author":"Xiao","year":"2025","journal-title":"Ther Adv Drug Saf"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1386-5056(00)00062-9","article-title":"The use of a medical dictionary for regulatory activities terminology (MedDRA) in prescription-event monitoring in Japan (J-PEM)","volume":"57","author":"Yokotsuka","year":"2000","journal-title":"Int J Med Inform"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction","volume":"45","author":"Kinoshita","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1521358","DOI":"10.3389\/fphar.2025.1521358","article-title":"Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database","volume":"16","author":"He","year":"2025","journal-title":"Front Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"938552","DOI":"10.3389\/fphar.2022.938552","article-title":"Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system","volume":"13","author":"Jeong","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"8045","DOI":"10.3390\/ijms24098045","article-title":"Topical treatment for retinal degenerative pathologies: a systematic review","volume":"24","author":"Samoil\u0103","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1080\/14712598.2022.2100694","article-title":"Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?","volume":"22","author":"Uludag","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/02713683.2024.2388698","article-title":"Slit2 promotes H2O2-induced lens epithelial cells oxidative damage and age-related cataract","volume":"50","author":"Fu","year":"2025","journal-title":"Curr Eye Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1080\/02713683.2023.2293456","article-title":"Oxidative stress participates in age-related cataract formation by disrupting connection between lens epithelial cells through c-src\/VEGF pathway","volume":"49","author":"Zhang","year":"2024","journal-title":"Curr Eye Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.ophtha.2024.02.022","article-title":"Phase 3 randomized clinical trial of the safety and efficacy of Travoprost intraocular implant in patients with open-angle glaucoma or ocular hypertension","volume":"131","author":"Sarkisian","year":"2024","journal-title":"Ophthalmology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.2147\/OPTH.S340386","article-title":"Efficacy and patient tolerability of Omidenepag isopropyl in the treatment of glaucoma and ocular hypertension","volume":"16","author":"Matsuo","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"100922","DOI":"10.1016\/j.ajps.2024.100922","article-title":"Glucocorticoids-based prodrug design: current strategies and research progress","volume":"19","author":"Liu","year":"2024","journal-title":"Asian J Pharm Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00467-021-04985-1","article-title":"Optimizing the corticosteroid dose in steroid-sensitive nephrotic syndrome","volume":"37","author":"Christian","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s42003-025-08067-y","article-title":"Upregulation of ferroptosis in glucocorticoids-induced posterior subcapsular cataracts","volume":"8","author":"Zhang","year":"2025","journal-title":"Commun Biol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1002\/art.42646","article-title":"2022 American College of Rheumatology Guideline for the prevention and treatment of Glucocorticoid-Induced osteoporosis","volume":"75","author":"Humphrey","year":"2023","journal-title":"Arthritis & Rheumatology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab Soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody\u2013drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1158\/1078-0432.CCR-23-0991","article-title":"FDA approval summary: Mirvetuximab soravtansine-gynx for FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"29","author":"Dilawari","year":"2023","journal-title":"Clin Cancer Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1266890","DOI":"10.3389\/fphar.2023.1266890","article-title":"Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study","volume":"14","author":"Yuan","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ydbio.2008.03.028","article-title":"Fibroblast growth factor receptor signaling is essential for lens fiber cell differentiation","volume":"318","author":"Zhao","year":"2008","journal-title":"Dev Biol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ydbio.2020.07.017","article-title":"Lens fiber cell differentiation occurs independently of fibroblast growth factor receptor signaling in the absence of Pten","volume":"467","author":"Padula","year":"2020","journal-title":"Dev Biol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1158\/1078-0432.CCR-23-1248","article-title":"Tamoxifen response at single-cell resolution in estrogen receptor-positive primary human breast tumors","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Cancer Res"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0002-9394(99)80190-1","article-title":"Long-term tamoxifen citrate use and potential ocular toxicity","volume":"125","author":"Gorin","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1172\/JCI117514","article-title":"Tamoxifen blocks chloride channels. A possible mechanism for cataract formation","volume":"94","author":"Zhang","year":"1994","journal-title":"J Clin Invest"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jad.2016.11.019","article-title":"Association between antipsychotic drug use and cataracts in patients with bipolar disorder: a population-based, nested case-control study","volume":"209","author":"Chu","year":"2017","journal-title":"J Affect Disord"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1176\/appi.psy.43.5.354","article-title":"Cataract occurrence with antipsychotic drugs","volume":"43","author":"Shahzad","year":"2002","journal-title":"Psychosomatics"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.molmed.2012.03.005","article-title":"Protein misfolding and aggregation in cataract disease and prospects for prevention","volume":"18","author":"Moreau","year":"2012","journal-title":"Trends Mol Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40263-020-00698-5","article-title":"Pharmacological management of the genetic generalised epilepsies in adolescents and adults","volume":"34","author":"Stephen","year":"2020","journal-title":"CNS Drugs"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1465747","DOI":"10.3389\/fneur.2024.1465747","article-title":"Assessing the effectiveness and safety of patisiran and vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review","volume":"15","author":"Karimi","year":"2024","journal-title":"Front Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"798695","DOI":"10.3389\/fneur.2022.798695","article-title":"The use of neuroimaging for predicting sumatriptan treatment response in patients with migraine","volume":"13","author":"Wu","year":"2022","journal-title":"Front Neurol"},{"key":"ref39","first-page":"902","article-title":"The discovery of the mode of action of nitisinone","volume":"12","author":"Lock","year":"2022","journal-title":"Meta"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/jmd2.12288","article-title":"Association of alkaptonuria and low dose nitisinone therapy with cataract formation in a large cohort of patients","volume":"63","author":"Ahmad","year":"2022","journal-title":"JIMD Rep"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/jop.2025.0030","article-title":"Beyond the prostate: a visionary study on ocular impacts of benign prostatic hyperplasia drugs","volume":"41","author":"Khan","year":"2025","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1758892\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:35:50Z","timestamp":1771918550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1758892\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":41,"alternative-id":["10.3389\/fmed.2026.1758892"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1758892","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"article-number":"1758892"}}